Multiple system atrophy (MSA)
Conditions
Interventions
PET with [18F] SPAL-T-06, [11C] PiB, and neuropsychological tests
PET with [18F] SPAL-T-06, [11C] PiB, and neuropsychological tests
Sponsors
Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology (QST)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: I. Patients 20 y.o.<=Age patients with multiple system atrophy (Gilman's criteria or MDS MSA criteria). II. Healthy volunteers 20 y.o.<=Age normal subjects
Exclusion criteria
Exclusion criteria: I. Patients 1. Subjects with a history or complications of cerebral diseases 2. Subjects with concomitant substance use disorders 3. Subjects with a history or complications of severe diseases 4. Subjects with magnetic metals in the body 5. Subjects with severe claustrophobia 6. Pregnant women 7. Subjects who are considered to be inappropriate to participate in the study II. Healthy volunteers 1. Subjects with a history or complications of cerebral diseases 2. Subjects with concomitant substance use disorders 3. Subjects with a history or complications of severe diseases 4. Subjects with magnetic metals in the body 5. Subjects with severe claustrophobia 6. Pregnant women 7. Subjects who are considered to be inappropriate to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The distribution of alpha-synuclein lesions in the brain in healthy volunteers and patients with multiple system atrophy (MSA) | — |
Countries
Japan
Contacts
Public ContactEndo Hironobu
Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, QST Department of Functional Brain Imaging
Outcome results
None listed